Angiotensin-(1-7): An active member of the renin - angiotensin system

Journal of Physiology and Pharmacology

Volumn 53, Issue 4 I, 2002, Pages 533-540

  Kucharewicz, I ^a   Pawlak, R ^a   Matys, T ^a   Chabielska, E ^a   Buczko, W ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Angiotensin receptors; Angiotensin (1 7); Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN[1-7];

ARRHYTHMOGENESIS; CONFERENCE PAPER; DIURESIS; MITOGENESIS; NATRIURESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM RETENTION; VASOCONSTRICTION; WATER RETENTION;

ANGIOTENSIN I; ANIMALS; CARDIOVASCULAR PHYSIOLOGY; CELL DIVISION; HUMANS; KIDNEY; PEPTIDE FRAGMENTS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; THROMBOSIS;

EID: 0036912679     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. Aurell M. The renin-angiotensin system: The centenary jubilee. Blood Press 1998; 7: 71-75.
2. Opolski G, Filipiak KJ. Drugs Blocking Renin-Angiotensin-Aldosteron System., Wroclaw, Urban & Partner, 2000.
3. Brosnihan KB. Effect of the angiotensin-(1-7) peptide on nitric oxide release. Am J Cardiol 1998; 82:17S-19S.
4. Brosnihan KB, Li P, Tallant EA, Ferrario CM. Angiotensin-(1-7): A novel vasodilator of the coronary circulation. Biol Res 1998;31:227-234.
5. Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999; 33: 207-211.
6. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997; 30: 535-541.
7. Ferreira AJ, Santos RA, Almeida AP. Angiotensin-(1-7): Cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 2001; 38: 665-668.
8. Kucharewicz I, Chabielska E, Pawlak D, Matys T, Rolkowski R, Buczko W. The antithrombotic effect of angiotensin-(1-7) closely resembles that of losartan. JRAAS 2000; 1: 268-272.
9. Kumamoto K, Stewart TA, Johnson AR, Erdos EG. Prolylcarboxypeptidase (angiotensinase C) in human lung and cultured cells. J Clin Invest 1981; 67: 210-215.
10. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-E9.
11. Chappell MC, Pirro NT, Sykes A, Ferrario CM. Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension 1998; 31: 362-367.
12. Ferrario, C. M. Biological roles of angiotensin-(1-7). Hypertens Res 1992; 15: 61-66.
13. Allred AJ, Diz DI, Ferrario CM, Chappell MC. Pathways for angiotensin-(1-7) metabolism in pulmonary and renal tissues. Am J Physiol Renal Physiol 2000; 279: F841-F850.
14. Burnett JC Jr. Vasopeptidase inhibition: A new concept in blood pressure management. J Hypertens Suppl 1999; 17: S37-S43.
15. Ferrario CM, Smith RD Yunis C. Angiotensin-(1-7) and vasopeptidase inhibition. 15th Scientific Meeting of the American Society of Hypertension, May 16-20, 2000, New York.
16. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996; 27: 523-528.
17. Meng W, Busija DW. Comparative effects of angiotensin-(1-7) and angiotensin II on piglet pial arterioles. Stroke 1993; 24: 2041-2044.
18. Osei SY, Ahima RS, Minkes RK, Weaver JP, Khosla MC, Kadowitz PJ. Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur J Pharmacol 1993; 234: 35-42.
19. Lima CV, Paula RD, Resende FL, Khosla MC, Santos RA. Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats. Hypertension 1997; 30: 542-548.
20. Li P, Chappell MC, Ferrario CM, Brosnihan KB. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 1997; 29: 394-400.
21. Loot AE, Roks AJ, Henning RH, et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002; 105: 1548-1550.
22. Silva-Barcellos NM, Frezard F, Caligiorne S, Santos RA. Long-lasting cardiovascular effects of liposome-entrapped angiotensin- (1-7) at the rostral ventrolateral medulla. Hypertension 2001; 38: 1266-1271.
23. Campagnole-Santos MJ, Heringer SB, Batista EN, Khosla MC, Santos RA. Differential baroreceptor reflex modulation by centrally infused angiotensin peptides. Am J Physiol 1992; 263: R89-R94.
24. Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998; 31: 699-705.
25. Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 1998; 31: 356-361.
26. Tallant EA, Diz DI, Ferrario CM. State-of-the-Art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension 1999; 34: 950-957.
27. Machado RD, Santos RA, Andrade SP. Opposing actions of angiotensins on angiogenesis. Life Sci 2000; 66: 67-76.
28. Chabielska E, Pawlak R, Wollny T, Rolkowski R, Buczko W. Antithrombotic activity of losartan in two kidney, one clip hypertensive rats. A study on the mechanism of action. J Physiol Pharmacol 1999; 50: 99-109.
29. Pawlak R, Chabielska E, Golatowski J, Azzadin A, Buczko W. Nitric oxide and prostacyclin are involved in antithrombotic action of captopril in venous thrombosis in rats. Thromb Haemost 1998; 79: 1208-1212.
30. Pawlak R, Chabielska E, Buczko W. Antithrombotic effect of enalapril, an angiotensin-converting enzyme inhibitor, on venous thrombosis in rats. Pol J Pharmacol 1996; 48: 117-120.
31. Chabielska E, Pawlak R, Buczko W. Effects of drugs affecting the renin-angiotensin system on venous thrombosis in normotensive rats. Pol J Pharmacol 1996; 48: 89-91.
32. Pawlak R, Chabielska E, Matys T et al. Thiol repletion prevents venous thrombosis in rats by nitric oxide/prostacyclin-dependent mechanism: Relation to the antithrombotic action of captopril. J Cardiovasc Pharmacol 2000; 36: 503-509.
33. Chabielska E, Matys T, Kucharewicz I. Pawlak D, Rolkowski R, Buczko W. The involvement of AT2-receptor in the antithrombotic effect of losartan in renal hypertensive rats. JRAAS 2000; 1: 263-267.
34. Chlopicki S, Koda M, Chabielska E, Buczko W, Gryglewski RJ. Antiplatelet action of losartan involves TXA2 receptor antagonism but not TXA2 synthase inhibition. J Physiol Pharmacol 2000; 51: 715-722.
35. Matys T, Chabielska E, Pawlak R, Kucharewicz I, Buczko W. Losartan inhibits the adhesion of rat platelets to fibrillar collagen - A potential role of nitric oxide and prostanoids. J Physiol Pharmacol 2000; 51: 705-713.
36. Nishimura H, Tsuji H, Masuda H, et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 1997; 77: 1189-1195.
37. Taubman MB, Marmur JD, Rosenfield CL, Guha A, Nichtberger S, Nemerson Y. Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells. Role of Ca2+ mobilization and protein kinase C activation. J Clin Invest 1993; 91: 547-552.
38. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95: 995-1001.
39. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969-1973.
40. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995; 95: 1353-1362.
41. Kucharewicz I, Buczko W. The antithrombotic action of angiotensin-(1-7) in experimental venous thrombosis model in renal hypertensive rats. Fibrynolysis and Proteolysis 2000: 14 suppl 1: 56.
42. Chappell MC, Diz DI, Yunis C, Ferrario CM. Differential actions of angiotensin-(1-7) in the kidney. Kidney Int Suppl 1998; 68: S3-S6.
43. Benter IF, Ferrario CM, Morris M, Diz DI. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol 1995; 269: H313-H319.
44. Vallon V, Heyne N, Richter K, Khosla MC, Fechter K. [7-D-ALA]-angiotensin 1-7 blocks renal actions of angiotensin 1-7 in the anesthetized rat. J Cardiovasc Pharmacol 1998; 32: 164-167.
45. Garcia NH, Garvin JL. Angiotensin 1-7 has a biphasic effect on fluid absorption in the proximal straight tubule. J Am Soc Nephrol 1994; 5: 1133-1138.
46. Roks AJ, van Geel PP, Pinto YM, et al. Angiotensin-(1-7) is a modulator of the human reninangiotensin system. Hypertension 1999; 34: 296-301.
47. Souza Dos Santos RA, Passaglio KT, Pesquero JB, Bader M, Simoes E Silva AC. Interactions between angiotensin-(1-7), kinins, and angiotensin II in kidney and blood vessels. Hypertension 2001; 38: 660-664.
48. Ambuhl P, Felix D, Khosla MC. [7-D-ALA]-angiotensin-(1-7): Selective antagonism of angiotensin-(1-7) in the rat paraventricular nucleus. Brain Res Bull 1994; 35: 289-291.
49. Tallant EA, Lu X, Weiss RB, Chappell MC, Ferrario CM. Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. Hypertension 1997; 29: 388-393.
50. Nickenig G, Geisen G, Vetter H, Sachinidis A. Characterization of angiotensin receptors on human skin fibroblasts. J Mol Med 1997; 75: 217-222.
51. Neuss M, Regitz-Zagrosek V, Hildebrandt A, Fleck E. Human cardiac fibroblasts express an angiotensin receptor with unusual binding characteristics which is coupled to cellular proliferation. Biochem Biophys Res Commun 1994; 204: 1334-1339.
52. Gironacci MM, Adler-Graschinsky E, Pena C, Enero MA. Effects of angiotensin II and angiotensin-(1-7) on the release of. Hypertension 1994; 24: 457-460.
53. Ueda S, Masumori-Maemoto S, Ashino K, et al. Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertension 2000; 35: 998-1001.
54. Gironacci MM, Coba MP, Pena C. Angiotensin-(1-7) binds at the type 1 angiotensin II receptors in rat renal cortex. Regul Pept 1999; 84: 51-54.
55. Moritz KM, Campbell DJ, Wintour EM. Angiotensin-(1-7) in the ovine fetus. Am J Physiol Regul Integr Comp Physiol 2001; 280: R404-R409.
56. Neves LA, Santos RA, Khosla MC, Milsted A. Angiotensin-(1-7) regulates the levels of angiotensin II receptor subtype AT1 mRNA differentially in a strain-specific fashion. Regul Pept 2000; 95: 99-107.
57. Clark MA, Diz DI, Tallant EA. Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells. Hypertension 2001; 37: 1141-1146.
58. Abbas A, Gorelik G, Carbini LA, Scicli AG. Angiotensin-(1-7) induces bradykinin-mediated hypotensive responses in anesthetized rats. Hypertension 1997; 30: 217-221.
59. Heitsch, H., Brovkovych, S., Malinski, T., and Wiemer, G. Angiotensin-(1-7)- stimulated nitric oxide and superoxide release from endothelial cells. Hypertension 2001; 37: 72-76.
60. Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, Erdos EG. N-domain-specific substrate and C-domain inhibitors of angiotensin- converting enzyme: Angiotensin-(1-7) and keto-ACE. Hypertension 1998; 31: 912-917.